<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002244</url>
  </required_header>
  <id_info>
    <org_study_id>CT-L08-101</org_study_id>
    <nct_id>NCT05002244</nct_id>
  </id_info>
  <brief_title>A Drug-Drug Interaction Study of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers</brief_title>
  <official_title>A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Phase 1 Study to Evaluate the Pharmacokinetic Interaction and Safety of CTL0801 and CTL0802 Compared to Coadministration in Healthy Adult Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celltrion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celltrion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a two-arm, open-label, single-sequence, multiple-dose, cross-over phase 1 study to&#xD;
      evaluate the interaction between two investigational drugs by comparing and analyzing the&#xD;
      pharmacokinetic interaction and safety of CTL0801 and CTL0802 at steady state when&#xD;
      administered alone or in combination with repeated oral doses in healthy adult volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2021</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss</measure>
    <time_frame>predose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and, 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss</measure>
    <time_frame>predose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and, 24 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tmax,ss</measure>
    <time_frame>predose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and, 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss</measure>
    <time_frame>predose(0 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and, 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Health, Subjective</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTL0801 (Azilsartan) QD, 4days → CTL0801 (Azilsartan) + CTL0802 (Rosuvasatin) QD, 7days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CTL0802 (Rosuvasatin) QD, 7days → CTL0801 (Azilsartan) + CTL0802 (Rosuvasatin) QD, 7days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTL0801 (Azilsartan)</intervention_name>
    <description>CTL0801 (Azilsartan), single dose, daily, repeated oral administration</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTL0802 (Rosuvastatin)</intervention_name>
    <description>CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin)</intervention_name>
    <description>CTL0801 (Azilsartan) + CTL0802 (Rosuvastatin), single dose, daily, repeated oral administration</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A subject who weighs 50 kg or more (45 kg or more for women)&#xD;
&#xD;
          -  A subject who does not have clinically significant congenital or chronic diseases&#xD;
&#xD;
          -  A subject who is judged to be eligible to participate by the results of diagnostic&#xD;
             tests by the principal investigator&#xD;
&#xD;
          -  A subject and their partner who agree to use a medically appropriate method of&#xD;
             contraception to exclude potential of pregnancy and not to provide sperm or ova from&#xD;
             the first dose to 7 days after the last dose of the investigational drug&#xD;
&#xD;
          -  A subject who voluntarily signs the consent form after hearing and understanding the&#xD;
             purpose and content of this study, the characteristics of the investigational drugs,&#xD;
             and expected adverse reactions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject who has a known digestive system, cardiovascular system, endocrine system,&#xD;
             respiratory system, blood·tumor, infectious disease, kidney and genitourinary system,&#xD;
             mental·nervous system, musculoskeletal system, immune system, otolaryngology, skin&#xD;
             system, ophthalmic system or has any past history of them&#xD;
&#xD;
          -  A subject who has a history of gastrointestinal surgery that may affect drug&#xD;
             absorption (except simple appendectomy or hernia surgery) or has gastrointestinal&#xD;
             diseases&#xD;
&#xD;
          -  A subject who has taken drugs that induce or inhibit drug metabolizing enzymes such as&#xD;
             barbiturates within 1 month of the first administration or has taken drugs that may&#xD;
             affect the study within 10 days of the first administration (however, participation&#xD;
             can be possible considering pharmacokinetic·pharmacodynamic characteristics such as&#xD;
             interaction with concomitant drugs and half-life of concomitant drugs etc)&#xD;
&#xD;
          -  A subject who has participated and administered other investigational drugs in other&#xD;
             clinical trials or bioequivalence studies within 6 months of the first administration&#xD;
&#xD;
          -  A subject who is judged ineligible for participation in this study by the principal&#xD;
             investigator&#xD;
&#xD;
          -  A female volunteer who is pregnant or lactating&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jaewoo Kim, PhD</last_name>
    <phone>07046659193</phone>
    <email>m3116@newyjh.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>H Plus Yangji Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaewoo Kim</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Azilsartan medoxomil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

